Shots: The P-III PROSPER study involves assessing of Xtandi (160mg, QD) + ADT vs PBO + ADT in 1400 patients with nmCRPC across the US, EU, SA, Canada, and the […]readmore
Tags : (enzalutamide)
Regulatory
Astellas’ Xtandi (enzalutamide) Receives NMPA’s Approval for Metastatic Castration-Resistant Prostate
Shots: The approval is based on P-III Asian PREVAIL study assessing Xtandi (160mg/day) vs PBO + GnRH therapy or after bilateral orchiectomy in patients with progressive metastatic mCRPC who had […]readmore
Shots: The P-III ARCHES trial involves assessing of Xtandi + ADT (enzalutamide, 160mg) vs ADT monothx in 1,150 men with mHSPC at the US, Canada, EU, South America P-III ARCHES […]readmore
Shots: The EU approval is based on results of P-III PROSPER trial assessing Xtandi+ ADT vs. PBO + ADT in patients with nmCRPC and PSA level The P-III PROSPER trial […]readmore